Skip to main content
SpringerLink
Log in

Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use

  • Review Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Over the past several decades, the use of intravenous human normal immunoglobulin (IVIg) products in a diverse range of immunodeficiency, inflammatory and infectious disorders has increased significantly.Newer manufacturing processes have increased the yield of intact IVIg molecules and have also improved the tolerability and safety of these products, including reducing the transmission risk of blood-borne diseases. While there are no appreciable differences between the numerous commercially available IVIg products in terms of efficacy, different manufacturing processes and the final composition of IVIg products have resulted in different safety and tolerability profiles. The tolerability profile of different IVIg products may be idiosyncratic for individual patients and may not be predictable, based on product characteristics.Consequently, patients receiving an IVIg product should be carefully monitored at initial exposure, and switching of products should be avoided. To achieve the best outcomes in patients requiring IVIg therapy,treatment should be tailored to the patient’s needs. The risk/benefit profile of an IVIg in relation to patient risk factors and the underlying immune deficiency, or autoimmune or inflammatory disorder should be considered when deciding on the most appropriate therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38(1–3): 122–32

    Article  PubMed  CAS  Google Scholar 

  2. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007; 1(1): 9–18

    Article  Google Scholar 

  3. Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008; 28(4): 737–64

    Article  PubMed  Google Scholar 

  4. Hartung H-P. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008; 255Suppl. 3: 3–6

    Article  PubMed  CAS  Google Scholar 

  5. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008; 28(4): 765–78

    Article  PubMed  Google Scholar 

  6. Gelfland EW. Critical decisions in selecting an intravenous immunoglobulin product. J Infus Nurs 2005; 28(6): 366–74

    Article  Google Scholar 

  7. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immmunology. J Allergy Clin Immunol 2006; 117(4 Suppl.): S525–53

    Article  PubMed  CAS  Google Scholar 

  8. ZLB Behring LLC. Immune globulin intravenous (human) Carimune® NF nanofiltered, lyophilized preparation: US prescribing information. Kankanee (IL): ZLB Behring LLC, 2005

    Google Scholar 

  9. Grifols Biologicals Inc. Flebogamma® 5% DIF immune globulin intravenous (human): US prescribing information. Los Angeles (CA): Grifols Biologicals Inc., 2006

    Google Scholar 

  10. Baxter Healthcare Corporation. Gammagard S/D [immune globulin intravenous (human)] solvent detergent treated IgA less than 1 μg/mL in a 5% solution: US prescribing information. Westlake Village (CA): Baxter Healthcare Corporation, 2007

    Google Scholar 

  11. Baxter Healthcare Corporation. Gammagard S/D immune globulin intravenous (human) IgA less than 2.2 μg/mL, in a 5% solution: US prescribing information. Westlake Village (CA): Baxter Healthcare Corporation, 2008

    Google Scholar 

  12. Baxter Healthcare Corporation. Gammagard liquid [immune globulin intravenous (human)] 10%: US prescribing information. Westlake Village (CA): Baxter Healthcare Corporation, 2005

    Google Scholar 

  13. 13. Talecris Biotherapeutics Inc. Gamunex® 10% liquid preparation immune globulin intravenous (human), 10% caprylate/chromatography purified: US prescribing information. Triangle Park (NC): Talecris Biotherapeutics Inc., 2008

    Google Scholar 

  14. Octapharma USA Inc. Octagam [immune globulin intravenous (human)] 5% liquid preparation: US prescribing information. Hoboken (NJ): Octapharma USA Inc., 2008

    Google Scholar 

  15. CSL Behring LLC. Immune globulin intravenous (human) 10% liquid. Privigen™: US prescribing information. Kankakee (IL): CSL Behring LLC, 2007

    Google Scholar 

  16. Novartis Pharmaceuticals Corporation. Immune globulin intravenous (human) Sandoglobulin®: US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2000

    Google Scholar 

  17. 17. Grifols UK Ltd. Flebogamma® 5% solution for infusion: summary of product characteristics. Cambridgeshire: Grifols UK Ltd, 2008

    Google Scholar 

  18. European Medicines Agency. Summary of product characteristics: Flebogammadif.2009 [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/flebogammadif/flebogammadif.htm [Accessed 2009 Sep 4]

  19. Kedrion SpA. IG Vena N IV: summary of product characteristics. Barga, Lucca: Kedrion SpA, 2001

    Google Scholar 

  20. Sanquin. Immunoglobuline IV: summary of product characteristics. Amsterdam: Sanquin, 2007

    Google Scholar 

  21. Biotest Pharma GmbH. Intratect 50 g/L, solution for infusion: summary of product characteristics. Dreieich: Biotest Pharma GmbH, 2007

    Google Scholar 

  22. European Medicines Agency. Kiovig 100 mg/mL solution for infusion: summary of product characteristics. 2006 [online]. Available from URL: http://www.ema.europa.eu/humandocs/Humans/EPAR/kiovig/kiovig.htm [Accessed 2009 Sep 17]

  23. Sanquin. Nanogam 50 mg/mL solution for infusion: summary of product characteristics [in Dutch]. Amsterdam: Sanquin, 2009

    Google Scholar 

  24. Octapharma Ltd. Normal intravenous immunoglobulin: Octagam® 50 mg/mL solution for infusion. Summary of product characteristics. Coventry: Octapharma Ltd, 2005

    Google Scholar 

  25. Octapharma Ltd. Human normal immunoglobulin for intravenous administration (IVIg) Octagam 10%: Octagam 100mg/mL. Summary of product characteristics. Coventry: Octapharma Ltd, 2008

    Google Scholar 

  26. European Medicines Agency. Privigen 100 mg/mL solution for infusion: summary of product characteristics. 2008 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/privigen/emea-com bined-h831en.pdf [Accessed 2009 Sep 17]

  27. European Medicines Agency. Assessment report for Privigen. 2008 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/privigen/H-831-en6.pdf [Accessed 2009 Sep 17]

  28. CSL Behring UK Limited. Sandoglobulin NF liquid, 120 mg/mL solution for infusion. Haywards Heath: CSL Behring UK Limited, 2008

    Google Scholar 

  29. HAS (Haute Autorite de Sante). Tegeline 50 mg/mL, poudre et solvant pour solution pour perfusion. 2007 [online]. Available from URL: http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-4164_tegeline_.pdf [Accessed 2010 May 3]

  30. BPL (Bio Products Laboratory). Vigam® liquid: UK prescribing information. Elstree: BPL, 2004

    Google Scholar 

  31. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis [see comment]. N Engl J Med 1993 Dec 30; 329(27): 1993–2000

    Article  PubMed  CAS  Google Scholar 

  32. Cherin P, Herson S, Wechsler B, et al. Intravenous immunoglobulin for polymyositis and dermatomyositis. Lancet 1990; 336: 116

    Article  PubMed  CAS  Google Scholar 

  33. Cherin P, Herson S, Wechsler B, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991 Aug; 91(2): 162–8

    Article  PubMed  CAS  Google Scholar 

  34. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002; 46: 467–74

    Article  PubMed  CAS  Google Scholar 

  35. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001 Feb 13; 56(3): 323–7

    Article  PubMed  CAS  Google Scholar 

  36. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002 Jan 22; 58(2): 326–7

    Article  PubMed  CAS  Google Scholar 

  37. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005; 62(16 Suppl. 3): S5–11

    Article  PubMed  Google Scholar 

  38. Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol 2006; 19(1): 3–25

    Article  PubMed  CAS  Google Scholar 

  39. Donofrio PD, Berger A, Brannagan 3rd TH, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 2009 Nov; 40(5): 890–900

    Article  PubMed  CAS  Google Scholar 

  40. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Saf 1999; 21(3): 171–85

    Article  PubMed  CAS  Google Scholar 

  41. Welles CC, Tanbra S, Lafayette RA. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010; 55(1): 148–51

    Article  PubMed  Google Scholar 

  42. European Medicines Agency. European Public Assessment Report. Procedural steps taken and scientific information after the authorisation: Flebogammadif. 2009 [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/flebogammadif/flebogammadif.htm [Accessed 2009 Sep 4]

  43. IPOPI. IPOPI global immunoglobulin list 2009 [online]. Available from URL: http://www.ipopi.org/documents/global-immunoglobulin-list/Ig%20Global%20list%202008-1112.htm [Accessed 2009 Jul 24]

  44. Shah SR. A newer immunoglobulin intravenous (IGIV)-Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care. Expert Opin Biol Ther 2008; 8(6): 799–804

    Article  PubMed  CAS  Google Scholar 

  45. European Medicines Agency. Flebogammadif 50 mg/mL solution for infusion: summary of product characteristics. 2009 [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/flebogammadif/emea-combined-h781en.pdf [Accessed 2009 Sep 3]

  46. Biotest Pharma GmbH. Intratect® product profile. 2009 [online]. Available from URL: http://www.biotest.de/ww/en/pub/plasmaproteins/immunoglobulins/intratect/product_profile.cfm [Accessed 2009 Sep 17]

  47. European Medicines Agency. Kiovig scientific discussion document. 2006 [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/kiovig/062806en6.pdf [Accessed 2009 Sep 17]

  48. Terpstra FG, Parkkinen J, Tolo H, et al. Viral safety of Nanogam®, a new 15nm-filtered liquid immunoglobulin product. Vox Sang 2006; 90: 21–32

    Article  PubMed  CAS  Google Scholar 

  49. CSL Behring. Manufacturing: partitioning/fractionation. 2009 [online]. Available from URL: http://www.cslbehring.com/s1/cs/enco/1196562782846/content/1196562782347/content.htm [Accessed 2009 Sep 23]

  50. LFB Biomedicaments. Tegeline 50 mg/mL powder and solvent for solution for infusion: summary of product characteristics. Courtaboeuf: LFB Biomedicaments, 2009

    Google Scholar 

  51. Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008 Jan; 58(1): 308–17

    Article  PubMed  CAS  Google Scholar 

  52. Godeau B, Caulier M-T, Decuypere L, et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 1999; 107: 716–9

    Article  PubMed  CAS  Google Scholar 

  53. BPL (Bio Products Laboratory). Therapy area-immunoglobulins. 2009 [online]. Available from URL: http://www.bpl.co.uk/public/therapy_areas/immunoglobulins/normal2.asp [Accessed 2009 Sep 21]

  54. More J. Characterization and formulation development of a new liquid intravenous immunoglobulin: Vigam Liquid. Paper presented at the first Plasma Products Biotechnology meeting; Queensland, Australia: March 27–30, 1999. Downstream 2000; 31: 22–33 [online]. Available from URL: http://www.gelifesciences.com/aptrix/upp00919.nsf/Content/50DD4C3FFD5A7070C1257628001CDDF7/$file/18114075.pdf [Accessed 2010 May 25]

  55. Kratz A, Lewandrowski KB. Case records of the Massachusetts General Hospital: normal reference laboratory values. N Engl J Med 1998; 339(15): 1063–72

    Article  PubMed  CAS  Google Scholar 

  56. Skvaril F, Gardi A. Differences among available immunoglobulin preparations for intravenous use. Pediatr Infect Dis J 1988; 7(5): S43–8

    PubMed  CAS  Google Scholar 

  57. Ballow M. Clinical and investigational considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005; 62(16 Suppl. 3): S12–8

    Article  PubMed  CAS  Google Scholar 

  58. Martin TD. IGIV: contents, properties, and methods of industrial production-evolving closer to a more physiologic product. Int Immunopharmacol 2006; 6(4): 517–22

    Article  PubMed  CAS  Google Scholar 

  59. Wassermann RL, Church JA, Peter HH, et al. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharm Sci 2009; 37: 272–8

    Article  Google Scholar 

  60. Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy 2005; 25 (11 Pt 2): 78S–84S

    Article  PubMed  CAS  Google Scholar 

  61. Stiehm ER. Lessons from Kawasaki disease: all brands of IVIG are not equal. J Pediatr 2006; 148(1): 6–8

    PubMed  Google Scholar 

  62. Elluru S, Van Huyen J-PD, Bayry J, et al. Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes [published erratum appears in Immunol Lett 2006 Nov; 107 (2): 182]. Immunol Lett 2006; 107(1): 58–62

    Article  PubMed  CAS  Google Scholar 

  63. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med 2008 Jul 17; 359(3): 307–9

    Article  PubMed  CAS  Google Scholar 

  64. Lux A, Aschermann S, Biburger M, et al. The pro and anti-inflammatory activities of immunoglobulin G. Ann Rheum Dis 2010 Jan; 69Suppl. 1: i92–6

    Article  PubMed  CAS  Google Scholar 

  65. Crow AR, Brinc D, Lazarus AH. New insight into the mechanism of action of IVIg: the role of dendritic cells. J Thromb Haemost 2009 Jul; 7Suppl. 1: 245–8

    Article  PubMed  CAS  Google Scholar 

  66. Grillo JA, Gorson KC, Ropper AH, et al. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology 2001; 57: 1699–701

    Article  PubMed  CAS  Google Scholar 

  67. Shah S, Vervan M. Use of IV immune globulin and occurrence of associated acute renal failure and thrombosis. Am J Health-Sys Pharm 2005; 62: 720–5

    Google Scholar 

  68. Vo AA, Cam V, Toyoda M, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol 2006; 1: 844–52

    Article  PubMed  CAS  Google Scholar 

  69. Kazatchkine M. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345(10): 747–55

    Article  PubMed  CAS  Google Scholar 

  70. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002; 59 Suppl.: S28–32

    Article  PubMed  CAS  Google Scholar 

  71. Wiles CM, Brown P, Chapel H, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry 2002; 72: 440–8

    PubMed  CAS  Google Scholar 

  72. Cunningham-Rundles C, Zhou Z, Mankarious S, et al. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993; 13: 272–8

    Article  PubMed  CAS  Google Scholar 

  73. Martin TD. Safety and tolerability of intravenous immunoglobulins. Electroenceph Clin Neurophysiol Suppl 1999; 50: 514–20

    CAS  Google Scholar 

  74. Berger M, Pinciaro PJ, for the Flebogamma 5% Investigators. Safety, efficacy and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency disease. J Clin Immunol 2004; 24(4): 389–96

    Article  PubMed  CAS  Google Scholar 

  75. Church JA, Leibl H, Stein MR, group eaTU-P-I-S. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol 2006; 26(4): 388–95

    Article  PubMed  CAS  Google Scholar 

  76. Ochs HD, Pinciaro PJ, Octagam Study G. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004 May; 24(3): 309–14

    Article  PubMed  CAS  Google Scholar 

  77. Godeau B, Lesage S, Divine M, et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993 Sep 1; 82(5): 1415–21

    PubMed  CAS  Google Scholar 

  78. Colovic M, Dimitrijevic M, Sonnenburg C, et al. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J 2003; 4(5): 358–62

    Article  PubMed  CAS  Google Scholar 

  79. Varga G, Volkova Z, Leibl H, et al. Efficacy and safety of the new intravenous immunoglobulin IGIV 10% in adults with chronic idiopathic thrombocytopenic purpura. Transfus Med Hemother 2006 Dec; 33(6): 509–14

    Article  Google Scholar 

  80. Zhang G, Lopez PHH, Sheikh KA. Comparison of different brands of IVIg in an in vitro model of immune neuropathy. J Neuroimmunol 2006; 173(1–2): 200–3

    Article  PubMed  CAS  Google Scholar 

  81. Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol 2003 Sep; 3(9): 1325–33

    Article  PubMed  CAS  Google Scholar 

  82. Bussel JB, Eldor A, Kelton JG, et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 2004 Apr; 91(4): 771–8

    PubMed  CAS  Google Scholar 

  83. Wolf HH, Davies SV, Borte M, et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003 Jan; 84(1): 45–53

    Article  PubMed  CAS  Google Scholar 

  84. Tsai MH, Huang YC, Yen MH, et al. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin [see comment]. J Pediatr 2006 Jan; 148(1): 38–43

    Article  PubMed  CAS  Google Scholar 

  85. Rosenfeld EA, Shulman ST, Corydon KE, et al. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. J Pediatr 1995 Jun; 126(6): 1000–3

    Article  PubMed  CAS  Google Scholar 

  86. Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007 Sep; 16(9): 1038–47

    Article  PubMed  CAS  Google Scholar 

  87. Bussel JB, Hanna K, The IGIV-C in ITP Study Group. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. Am J Hematol 2007; 82: 192–8

    Article  PubMed  CAS  Google Scholar 

  88. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6(4): 535–42

    Article  PubMed  CAS  Google Scholar 

  89. Brennan VM, Salome-Bentley NJ, Chapel HM, Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003 Aug; 133(2): 247–51

    Article  PubMed  CAS  Google Scholar 

  90. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003 Oct; 17(4): 241–51

    Article  PubMed  Google Scholar 

  91. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol 2008 Dec; 122(6): 1238–9

    Article  PubMed  Google Scholar 

  92. Robak T, Mainau C, Pyringer B, et al. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (Octagam®10%) in patients with immune thrombocytopenia. Hematology. In press

  93. Katz U, Kishner I, Maglashvili D, et al. Long term safety of IVIG therapy in multiple sclerosis: 10 years experience. Autoimmunity 2006; 39(6): 513–7

    Article  PubMed  Google Scholar 

  94. Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008 Aug; 48(8): 1598–601

    Article  PubMed  Google Scholar 

  95. Rodriguez-Baez G, Lin RY. Intravenous immunoglobulin-associated renal failure reported between 2004–2008 [abstract no. 515]. J Allergy Clin Immunol 2010; 125(2 Suppl. 1): AB131

    Article  Google Scholar 

  96. Canadian Blood Services. Important information regarding IVIG-associated hemolysis. 2009 [online]. Available from URL: http://www.bloodservices.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/resources/Customer Letters09/$file/CL_2009-02.pdf [Accessed 2009 Sep 4]

  97. Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology 2009; 14(4): 227–36

    Article  PubMed  CAS  Google Scholar 

  98. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259–62

    PubMed  CAS  Google Scholar 

  99. Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol 2006; 6(4): 523–7

    Article  PubMed  CAS  Google Scholar 

  100. Reid B, Van Allen D, LaGrange CA, et al. Protocol recommendations for administration of intravenous immunoglobulin in Canada. J Infus Nurs 2006; 29(3): 158–64

    Article  PubMed  Google Scholar 

  101. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005; 16: 313–6

    Article  PubMed  CAS  Google Scholar 

  102. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994 Feb 01; 44: 223–6

    Article  PubMed  CAS  Google Scholar 

  103. CSL Behring Canada Ltd. Sandoglobulin® NF Liquid immune globulin intravenous (human) 12% solution for infusion: Canadian product monograph. Ottawa (ON): CSL Behring Canada Ltd, 2007

    Google Scholar 

Download references

Acknowledgments

We thank Susan Keam of inScience Communications, who provided medical writing support funded by Octapharma. No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Service de Médecine Interne I, Hôpital Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, 75651, Paris Cedex 13, France

    Patrick Chérin MD, PhD

  2. Service de Médecine Interne Horloge 2, Hôpital Saint Antoine, Paris, France

    Jean Cabane

Authors
  1. Patrick Chérin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean Cabane
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Chérin MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chérin, P., Cabane, J. Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use. BioDrugs 24, 211–223 (2010). https://doi.org/10.2165/11537660-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11537660-000000000-00000

Keywords

Search

Navigation